SYShengxia Yin

Shengxia Yin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shengxia Yin has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Chao Wu

    Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China

    6 shared publications
  • Jie Li

    Department of Infectious Diseases Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing Jiangsu China

    3 shared publications
  • Jie Li

    Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

    2 shared publications
  • Minxin Mao

    Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University of Chinese Medicine

    2 shared publications
  • Xin Tong

    Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

    2 shared publications
  • Xin Tong

    Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA

    2 shared publications

Latest Publications

  • Open Access

    Activated circulating T follicular helper 17 cells positively correlated with anti-HBV humoral immunity in chronic hepatitis B patients

    by Qi Gu, Minxin Mao, Yuan Liu, Xin Tong, Juan Zhang, Jinqiu Ran, Xiaoyan Ma, Juan Xia, Rui Huang, Jie Li, et al.

    Introduction: Dysfunction of hepatitis B virus (HBV)-specific B cells and lack of antibodies against hepatitis B surface antigen (HBsAg) are associated with failure to achieve functional cure in chronic hepatitis B (CHB). Follicular helper T (Tfh) cells are essential for B-cell differentiation into plasma cells and comprise three subsets: Tfh1, Tfh2, and Tfh17 cells. Our previous studies suggested dysregulated Tfh responses in CHB patients. However, the functions of Tfh cell subsets in CHB progression and treatment remain incompletely characterized. Methods: To explore the role of Tfh subgroups in HBV infection, we analyzed the frequencies of total and HBsAg-specific Tfh cell subsets and their surface markers using flow cytometry. Results: Compared with healthy individuals [healthy controls (HCs)], CHB patients had significantly higher frequencies of total Tfh cells, lower frequencies of Tfh17 cells and increased PD-1 expression. The frequency of quiescent Tfh17 cells negatively correlated with HBsAg + B cells and positively correlated with total immunoglobulin G (IgG). Further analysis revealed positive correlations between the frequency of quiescent Tfh17 cells and IgG1 and IgG3 levels. Discussion: These results suggest that Tfh17 frequency varies across immune phases in chronic HBV infection and that Tfh17 cells correlate with the immune response against chronic HBV infection. Importance: HBV is a major global public health problem. Dysfunction of HBV-specific B cells is an important reason for the failure to achieve a functional cure for HBV. Tfh cells are dysregulated in CHB patients, potentially leading to impaired B-cell differentiation into plasma cells. Here, we found that although Tfh17 cell frequencies were decreased in CHB patients, they exhibited a more activated state. Activated Tfh17 cells correlated positively with HBsAg levels, while quiescent Tfh17 cells correlated negatively. Furthermore, CHB patients had higher frequencies of HBV-specific Tfh17 cells, which positively correlated with serum HBsAg and HBV DNA levels. Our study provides new insights into the role of Tfh17 cells in CHB infection, potentially informing immunotherapeutic strategies for functional cure.


  • Open Access

    Key role of macrophages in the progression of hepatic fibrosis

    by Jinqiu Ran, Shengxia Yin, Rahma Issa, Qianwen Zhao, Guangqi Zhu, Huan Zhang, Qun Zhang, Chao Wu, Jie Li

    Liver fibrosis is a pathological change characterized by excessive deposition of extracellular matrix caused by chronic liver injury, and the mechanisms underlying its development are associated with endothelial cell injury, inflammatory immune cell activation, and HSC activation. Furthermore, hepatic macrophages exhibit remarkable heterogeneity and hold central functions in the evolution of liver fibrosis, with different subgroups exerting dual effects of promotion and regression. Currently, targeted macrophage therapy for reversing hepatic fibrosis has been extensively studied and has shown promising prospects. In this review, we will discuss the dual role of macrophages in liver fibrosis and provide new insights into reversing liver fibrosis based on macrophages.


  • The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes

    by Xiaoyan Ma, Yixuan Zhu, Yee Hui Yeo, Zhiwen Fan, Xiaoming Xu, Fajuan Rui, Wenjing Ni, Qi Gu, Xin Tong, Shengxia Yin, et al.

    Background and aims Data on the effects of liver fibrosis and hepatic steatosis on outcomes in individuals living with diabetes are limited. Therefore, we investigated the predictive value of the fibrosis and the severity of hepatic steatosis for all-cause mortality in individuals living with diabetes. Methods A total of 1903 patients with diabetes from the Third National Health and Nutrition Examination Survey (NHANES III) dataset were enrolled. Presumed hepatic fibrosis was evaluated with Fibrosis-4 index (FIB-4). The mortality risk and corresponding hazard ratio (HR) were analyzed with the Kaplan–Meier method and multivariable Cox proportional hazard models. Results Over a median follow-up of 19.4 years, all-cause deaths occurred in 69.6%. FIB-4 ≥ 1.3 was an independent predictor of mortality in individuals living with diabetes (HR 1.219, 95% confidence interval [CI]: 1.067–1.392, p = 0.004). Overall, FIB-4 ≥ 1.3 without moderate–severe steatosis increased the mortality risk (HR 1.365; 95%CI 1.147–1.623, p < 0.001). The similar results were found in individuals living with diabetes with metabolic dysfunction-associated fatty liver disease (MAFLD) (HR 1.499; 95%CI 1.065–2.110, p = 0.020), metabolic syndrome (MetS) (HR 1.397; 95%CI 1.086–1.796, p = 0.009) or abdominal obesity (HR 1.370; 95%CI 1.077–1.742, p = 0.010). Conclusions Liver fibrosis, as estimated by FIB-4, may serve as a more reliable prognostic indicator for individuals living with diabetes than hepatic steatosis. Individuals living with diabetes with FIB-4 ≥ 1.3 without moderate–severe steatosis had a significantly increased all-cause mortality risk. These findings highlight the importance of identifying and monitoring those individuals, as they may benefit from further evaluation and risk stratification. Graphical abstract


  • Open Access

    Histological features of chronic hepatitis B patients with normal alanine aminotransferase according to different criteria

    by Rui Huang, Jiacheng Liu, Jian Wang, Yuanwang Qiu, Li Zhu, Yiguang Li, Yilin Liu, Jie Zhan, Ruifei Xue, Suling Jiang, et al.

    Background: The upper limits of normal (ULNs) for alanine aminotransferase (ALT) are different among international guidelines for chronic hepatitis B (CHB). We aimed to investigate the proportion of significant histological disease in Asian patients with CHB with detectable hepatitis B virus (HBV) DNA under diverse ALT ULNs. Methods: Consecutive patients with CHB and detectable HBV DNA who underwent liver biopsy were retrospectively included from four tertiary hospitals. Above grade 2 inflammation and stage 2 fibrosis were defined as significant inflammation and significant fibrosis, respectively. Significant histological disease was defined as above grade 2 inflammation or stage 2 fibrosis. Results: Among the 414 patients with detectable HBV DNA and normal ALT, the proportion of those with significant histological disease was lower (59.7%) according to the ULN for ALT at 30/19 U/L (male/female), while the corresponding proportions were 66.7% and 62.3% according to the ULNs of 40 U/L and 35/25 U/L (male/female), respectively. In patients with detectable HBV DNA and normal ALT levels without significant fibrosis, the proportions of significant inflammation were comparable among different ULNs of ALT at 40 U/L (30.7%), 35/25 U/L (27.3%) and 30/19 U/L (25.0%). The proportion of significant histological disease was significantly lower in patients with normal ALT for 2 determinations at least 6 months apart compared to patients with normal ALT once. Conclusions: Although a more stringent ALT ULN may reduce the risk of the presence of significant histological disease in patients with detectable HBV DNA, the rates of significant histological disease remain high. Persistently normal ALT levels are more important for excluding patients with CHB with a high probability of significant histological disease.


  • Open Access

    Serum CXCL16: A new predictor of liver inflammation in patients with chronic hepatitis B

    by Yawen Wan, Minxin Mao, Ming Li, Jiacheng Liu, Xin Tong, Jian Wang, Jie Li, Shengxia Yin, Chao Wu

    The prompt initiation of antiviral therapy is essential in patients with chronic hepatitis B (CHB), especially when severe liver inflammation is detected. However, transcutaneous liver puncture, the gold standard for assessing liver inflammation, is invasive and its widespread application is limited. Therefore, there is an urgent need for more non‐invasive markers to predict liver inflammation. In our retrospective cross‐sectional study, which included 120 CHB patients and 31 healthy subjects, we observed a significant increase in serum chemokine C‐X‐C‐motif ligand 16 (CXCL16) in CHB patients compared to healthy controls (p < .001). Notably, patients with severe inflammation (Scheuer's grade G ≥ 3, n = 26) exhibited a substantial increase in serum CXCL16 compared to those with non‐severe inflammation (Scheuer's grade G < 3, n = 96) [(median, IQR), 0.42 (0.24–0.71) ng/mL vs. 1.01 (0.25–2.09) ng/mL, p < .001]. Furthermore, we developed a predictive model that combined CXCL16 with platelet count (PLT), alanine aminotransferase (ALT) and albumin (ALB) to accurately predict liver inflammation in CHB patients. This model was more effective than ALT alone in predicting liver inflammation (AUC, 0.92 vs. 0.81, p = .015). Additionally, using an HBV‐transduced mouse model, we demonstrated that blocking CXCL16 led to a reduction in liver inflammation and impaired infiltration and function of natural killer T (NKT) and natural killer (NK) cells. These findings suggest that CXCL16 is a promising non‐invasive biomarker of liver inflammation in CHB patients and may play a role in inducing liver inflammation via a NKT and NK cell pathway.